BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6431104)

  • 1. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.
    Jones CD; Jevnikar MG; Pike AJ; Peters MK; Black LJ; Thompson AR; Falcone JF; Clemens JA
    J Med Chem; 1984 Aug; 27(8):1057-66. PubMed ID: 6431104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
    Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
    J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat.
    Neubauer BL; Best KL; Clemens JA; Gates CA; Goode RL; Jones CD; Laughlin ME; Shaar CJ; Toomey RE; Hoover DM
    Prostate; 1993; 23(3):245-62. PubMed ID: 8234067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens.
    Wakeling AE; Valcaccia B
    J Endocrinol; 1983 Dec; 99(3):455-64. PubMed ID: 6644236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of estrogen action with a new benzothiophene derived antiestrogen.
    Black LJ; Jones CD; Falcone JF
    Life Sci; 1983 Feb; 32(9):1031-6. PubMed ID: 6827921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
    Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
    Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of androgen and estrogen effects in guinea pig seminal vesicle epithelium and fibromuscular stroma by keoxifene (LY156758).
    Neubauer BL; Biser P; Jones CD; Mariotti A; Hoover DM; Thornton T; Thornton MO; Goode RL
    Prostate; 1989; 15(3):273-86. PubMed ID: 2531383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
    Clemens JA; Bennett DR; Black LJ; Jones CD
    Life Sci; 1983 Jun; 32(25):2869-75. PubMed ID: 6406781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular determinants of tissue selectivity in estrogen receptor modulators.
    Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
    Gauthier S; Caron B; Cloutier J; Dory YL; Favre A; Larouche D; Mailhot J; Ouellet C; Schwerdtfeger A; Leblanc G; Martel C; Simard J; Mérand Y; Bélanger A; Labrie C; Labrie F
    J Med Chem; 1997 Jul; 40(14):2117-22. PubMed ID: 9216828
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular structures, conformational analysis, and preferential modes of binding of 3-aroyl-2-arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl azide photoaffinity labeling analogs.
    Kym PR; Anstead GM; Pinney KG; Wilson SR; Katzenellenbogen JA
    J Med Chem; 1993 Nov; 36(24):3910-22. PubMed ID: 8254621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
    Suh N; Glasebrook AL; Palkowitz AD; Bryant HU; Burris LL; Starling JJ; Pearce HL; Williams C; Peer C; Wang Y; Sporn MB
    Cancer Res; 2001 Dec; 61(23):8412-5. PubMed ID: 11731420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
    Jordan VC; Gosden B
    Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.
    di Salle E; Zaccheo T; Ornati G
    J Steroid Biochem; 1990 Jun; 36(3):203-6. PubMed ID: 2142233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
    Hartmann RW; Heindl A; Schneider MR; Schönenberger H
    J Med Chem; 1986 Mar; 29(3):322-8. PubMed ID: 3005573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydroxyphenyl)ethanes.
    Hartmann RW; Schwarz W; Heindl A; Schönenberger H
    J Med Chem; 1985 Sep; 28(9):1295-301. PubMed ID: 2993619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.